Physician profile
Daniel Vesco
NPI 1609370998
$974.12
in general payments reported to CMS, 2019-2025
14 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.62 · 2021: $39.17 · 2022: $40.72 · 2023: $617 · 2024: $71.14 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $260.79 | 2023-2025 | Novasure, Coolseal Generator, Aptima |
| Myriad Women'S Health, INC. | $229.98 | 2023 | Myrisk |
| Organon LLC | $110.62 | 2021-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $104.01 | 2023-2025 | Myfembree |
| Agile Therapeutics, INC. | $72.88 | 2023-2024 | Twirla |
| Biogen, INC. | $49.22 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $28.55 | 2023-2024 | Nuvessa, Slynd |
| Eisai INC. | $19.28 | 2021 | |
| Abbvie INC. | $18.90 | 2023 | Lo Loestrin Fe, Orilissa |
| Evofem Biosciences, INC. | $18.53 | 2022 | |
| Medtronic, INC. | $18.02 | 2025 | Truclear |
| Merck Sharp & Dohme LLC | $14.62 | 2019 | |
| Gynesonics, INC. | $14.55 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Astellas Pharma US INC | $14.17 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vesco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.